Download PDF
CC BY 4.0 · TH Open 2021; 05(01): e43-e55
DOI: 10.1055/s-0040-1722612
Original Article

A Matter of Caution: Coagulation Parameters in COVID-19 Do Not Differ from Patients with Ruled-Out SARS-CoV-2 Infection in the Emergency Department

Wolfgang Bauer
1   Department of Emergency Medicine, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
,
Noa Galtung
1   Department of Emergency Medicine, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
,
Nick Neuwinger
2   Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3   Labor Berlin—Charité Vivantes GmbH, Berlin, Germany
,
Lutz Kaufner
4   Department of Anesthesiology and Operative Intensive Care Medicine, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt—Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
,
Elisabeth Langer
2   Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3   Labor Berlin—Charité Vivantes GmbH, Berlin, Germany
,
Rajan Somasundaram
1   Department of Emergency Medicine, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
,
Rudolf Tauber
2   Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3   Labor Berlin—Charité Vivantes GmbH, Berlin, Germany
,
Kai Kappert
2   Institute of Laboratory Medicine, Clinical Chemistry and Pathobiochemistry, Charité—Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
3   Labor Berlin—Charité Vivantes GmbH, Berlin, Germany
› Author Affiliations Funding The authors acknowledge support from the German Research Foundation (DFG) and the Open Access Publication Fund of Charité–Universitätsmedizin Berlin.
› Further Information
   Permissions and Reprints

Abstract

COVID-19 (coronavirus disease 2019) patients often show excessive activation of coagulation, associated with increased risk of thrombosis. However, the diagnostic value of coagulation at initial clinical evaluation is not clear. We present an in-depth analysis of coagulation in patients presenting to the emergency department (ED) with suspected COVID-19. N = 58 patients with clinically suspected COVID-19 in the ED were enrolled. N = 17 subsequently tested positive using SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) polymerase chain reaction (PCR) swabs, while in n = 41 COVID-19 was ruled-out. We analyzed both standard and extended coagulation parameters, including thromboplastin time (INR), activated partial thromboplastin time (aPTT), antithrombin, plasminogen, plasminogen activator inhibitor-1 (PAI-1), D-dimers, and fibrinogen at admission, as well as α2-antiplasmin, activated protein C -resistance, factor V, lupus anticoagulant, protein C, protein S, and von Willebrand diagnostics. These data, as well as mortality and further laboratory parameters, were compared across groups based on COVID-19 diagnosis and severity of disease. In patients with COVID-19, we detected frequent clotting abnormalities, including D-dimers. The comparison cohort in the ED, however, showed similarly altered coagulation. Furthermore, parameters previously shown to distinguish between severe and moderate COVID-19 courses, such as platelets, plasminogen, fibrinogen, aPTT, INR, and antithrombin, as well as multiple nonroutine coagulation analytes showed no significant differences between patients with and without COVID-19 when presenting to the ED. At admission to the ED the prevalence of coagulopathy in patients with COVID-19 is high, yet comparable to the non-COVID-19 cohort presenting with respiratory symptoms. Nevertheless, coagulopathy might worsen during disease progression with the need of subsequent risk stratification.

Keywords

D-dimer - COVID-19 - risk stratification - emergency department - intensive care unit

Supplementary Material



Publication History

Received: 07 November 2020

Accepted: 30 November 2020

Article published online:
06 February 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Guan WJ, Ni ZY, Hu Y. et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382 (18) 1708-1720
    CrossrefPubMedGoogle Scholar
  • 2 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395 (10223): 497-506
    CrossrefPubMedGoogle Scholar
  • 3 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18 (04) 844-847
    CrossrefPubMedGoogle Scholar
  • 4 Gencer S, Lacy M, Atzler D, van der Vorst EPC, Döring Y, Weber C. Immunoinflammatory, thrombohaemostatic, and cardiovascular mechanisms in COVID-19. Thromb Haemost 2020; 120 (12) 1629-1641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Schulman S, Hu Y, Konstantinides S. Venous thromboembolism in COVID-19. Thromb Haemost 2020; 120 (12) 1642-1653
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Bilaloglu S, Aphinyanaphongs Y, Jones S, Iturrate E, Hochman J, Berger JS. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020; 324 (08) 799-801
    CrossrefPubMedGoogle Scholar
  • 7 Klok FA, Kruip MJHA, van der Meer NJM. et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-147
    CrossrefPubMedGoogle Scholar
  • 8 Grandmaison G, Andrey A, Périard D. et al. Systematic screening for venous thromboembolic events in COVID-19 pneumonia. TH Open 2020; 4 (02) e113-e115
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395 (10229): 1054-1062
    CrossrefPubMedGoogle Scholar
  • 10 Chen T, Wu D, Chen H. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368: m1091
    CrossrefPubMedGoogle Scholar
  • 11 Chen G, Wu D, Guo W. et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130 (05) 2620-2629
    CrossrefPubMedGoogle Scholar
  • 12 Gerotziafas GT, Sergentanis TN, Voiriot G. et al. Derivation and validation of a predictive score for disease worsening in patients with COVID-19. Thromb Haemost 2020; 120 (12) 1680-1690
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Han W, Quan B, Guo Y. et al. The course of clinical diagnosis and treatment of a case infected with coronavirus disease 2019. J Med Virol 2020; 92 (05) 461-463
    CrossrefPubMedGoogle Scholar
  • 14 Han H, Yang L, Liu R. et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020; 58 (07) 1116-1120
    CrossrefPubMedGoogle Scholar
  • 15 Bowles L, Platton S, Yartey N. et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med 2020; 383 (03) 288-290
    CrossrefPubMedGoogle Scholar
  • 16 Bi X, Su Z, Yan H. et al. Prediction of severe illness due to COVID-19 based on an analysis of initial fibrinogen to albumin ratio and platelet count. Platelets 2020; 31 (05) 674-679
    CrossrefPubMedGoogle Scholar
  • 17 Liao D, Zhou F, Luo L. et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol 2020; 7 (09) e671-e678
    CrossrefPubMedGoogle Scholar
  • 18 Bikdeli B, Talasaz AH, Rashidi F. et al. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: rationale and design of the INSPIRATION/INSPIRATION-S studies. Thromb Res 2020; 196: 382-394
    CrossrefPubMedGoogle Scholar
  • 19 Zhu J, Pang J, Ji P. et al. Coagulation dysfunction is associated with severity of COVID-19: a meta-analysis. J Med Virol 2020; 24: 1002
    PubMedGoogle Scholar
  • 20 Marchandot B, Trimaille A, Curtiaud A. et al. Staging severity of COVID-19 according to hemostatic abnormalities (CAHA Score). Thromb Haemost 2020; 120 (12) 1716-1719
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Ji HL, Zhao R, Matalon S, Matthay MA. Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility. Physiol Rev 2020; 100 (03) 1065-1075
    CrossrefPubMedGoogle Scholar
  • 22 Medcalf RL, Keragala CB, Myles PS. Fibrinolysis and COVID-19: a plasmin paradox. J Thromb Haemost 2020; 18 (09) 2118-2122
    CrossrefPubMedGoogle Scholar
  • 23 Wu Y, Wang T, Guo C. et al. Plasminogen improves lung lesions and hypoxemia in patients with COVID-19. QJM 2020; 113 (08) 539-545
    CrossrefPubMedGoogle Scholar
  • 24 Liu ZH, Wei R, Wu YP. et al. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. Biomed Environ Sci 2005; 18 (04) 260-264
    PubMedGoogle Scholar
  • 25 Nougier C, Benoit R, Simon M. et al. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis. J Thromb Haemost 2020; 18 (09) 2215-2219
    CrossrefPubMedGoogle Scholar
  • 26 Wang J, Hajizadeh N, Moore EE. et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost 2020; 18 (07) 1752-1755
    CrossrefPubMedGoogle Scholar
  • 27 Christie III DB, Nemec HM, Scott AM. et al. Early outcomes with utilization of tissue plasminogen activator in COVID-19-associated respiratory distress: a series of five cases. J Trauma Acute Care Surg 2020; 89 (03) 448-452
    CrossrefPubMedGoogle Scholar
  • 28 Gao Y, Li T, Han M. et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92 (07) 791-796
    CrossrefPubMedGoogle Scholar
  • 29 Wan S, Xiang Y, Fang W. et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020; 92 (07) 797-806
    CrossrefPubMedGoogle Scholar
  • 30 Lin J, Yan H, Chen H. et al. COVID-19 and coagulation dysfunction in adults: a systematic review and meta-analysis. J Med Virol 2021; 93 (02) 934-944
    CrossrefPubMedGoogle Scholar
  • 31 Ranucci M, Ballotta A, Di Dedda U. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020; 18 (07) 1747-1751
    CrossrefPubMedGoogle Scholar
  • 32 Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta 2020; 506: 145-148
    CrossrefPubMedGoogle Scholar
  • 33 Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8 (05) 475-481
    CrossrefPubMedGoogle Scholar
  • 34 Gatto M, Perricone C, Tonello M. et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases. Clin Exp Rheumatol 2020; 38 (04) 754-759
    PubMedGoogle Scholar
  • 35 McNabb-Baltar J, Jin DX, Grover AS. et al. Lipase elevation in patients with COVID-19. Am J Gastroenterol 2020; 115 (08) 1286-1288
    CrossrefPubMedGoogle Scholar
  • 36 Nadkarni GN, Lala A, Bagiella E. et al. Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19. J Am Coll Cardiol 2020; 76 (16) 1815-1826
    CrossrefPubMedGoogle Scholar
  • 37 Gerotziafas GT, Catalano M, Colgan MP. et al; Scientific Reviewer Committee. Guidance for the management of patients with vascular disease or cardiovascular risk factors and COVID-19: position paper from vas-european independent foundation in angiology/vascular medicine. Thromb Haemost 2020; 120 (12) 1597-1628
    Article in Thieme ConnectPubMedGoogle Scholar
  • 38 Golemi L, Hanson P, Tafur A. Frequently asked questions about thrombosis during COVID-19 pandemic. TH Open 2020; 4 (04) e303-e304
    Article in Thieme ConnectPubMedGoogle Scholar